anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a powdery composition capable of effectively adsorbing and decomposing the dirt and metabolic waste on the skin surface or in the pare by including calcium phosphate compound a particles holding a proteinase impregnated in or attached to the particles. CONSTITUTION:The calcium phosphate compound particle to be used in this composition has a Ca/P ratio of 1.5-1.8 and is composed of 5-95wt.% of porous spherical particles having an average particle diameter of 5-207mum and 5-95wt.% of fine particles having an average particle diameter of 0.1-5mum. Hydroxyapatite is preferable as the calcium phosphate compound. The calcium phosphate compound particle contains a proteinase at a weight ratio (proteinase/particle) of 1:(1-10). The enzyme is composed of at least one kind of substance selected from papain, bromelain, ficin, pancreatin and microbial protease. The composition contains 50-90wt.% (based on the total powder composition) of a water-soluble natural polymer compound having hydroxyl group (e.g. starch).
A B S T R A C T            This invention relates to methods for modulating the effects of TNF and IL-1, both the deleterious and the therapeutical effect of these cytokines.  In case of deleterious effects, the invention provides methods for modulating the deleterious effect of TNF and/or IL-1 in mammals, by administering to a mammal sub-deleterious amounts of TNF and/or IL-1.  The TNF and/or IL-1 to be modulated may be endogenous, i.e. generated in the organism in severe cases in amounts deleterious to the organism, or exogenously administered to a patient in amounts which are potentially deleterious.  The compositions of the invention comprise effective amounts of TNF and/or IL-1 with at least one pharmaceutically acceptable carrier.  The invention also relates to methods for monitoring the modulation of the TNF effect in patients treated with TNF and/or IL-1.
Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen- binding fragments, cells expressing the provided CD79b-specific antibodies or antigen- binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.
FIELD: pharmacy. SUBSTANCE: invention relates to pharmaceutical compositions promoting percutaneous absorption of substances. System consists of nonpermeable backing, polymeric diffusion matrix formed, preferably, by one or some thin layers and external layer. Matrix consists of, wt.-%: adhesive material 35-90; substances promoting absorption and retaining piroxicam in dissolved state 9-40; penetration enhancers 0.5-10, and active component 0.5-25. Adhesive polymers can be based on water and solvent. Polymers do two functions: they show adhesive property for skin, retain matrix on skin at good diffusion contact with skin and they are carriers of active substance or depot of active substance. Adhesive polymer is, preferably, vinyl-acetate-acrylate multipolymer. EFFECT: enhanced effectiveness of system. 6 cl, 3 dwg
Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates, wherein doxorubicin and sclareol are covalently linked by the linker in molar ratio 1:1. The hybrids show antitumor properties including the effects on resistant tumor cells characterized by the presence of the P-glycoprotein membrane transporter responsible for resistance to doxorubicin. The antitumor effect on different types of cell lines, namely human glioblastoma, non-small cell lung cancer, and colorectal cancer in mammals, especially humans, as well as the procedure for their preparation and use in medical products or pharmaceutical preparations, was determined. Available results include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant tumor cells (with and without P-glycoprotein expression). Selectivity towards tumor cells was determined by comparison with commercially available normal human lung fibroblast cells. Cellular uptake as well as intracellular localization of doxorubicin and its conjugates with sclareol were also investigated.
BACKGROUND: The most common method of inducing brain death in rats is inflating an intracranially placed balloon of a Fogarty catheter inserted through a burr hole. However, because of the poor controllability of balloon position, the standardization and stability of the model are compromised. This study examined an improved technique in which the balloon is placed and fixed through double holes.
METHODS: Forty adult male Sprague-Dawley (SD) rats were randomly and equally assigned into the single-hole (SH) group and the double-hole (DH) group. In each rat in the DH group, 2 holes were made, at the left frontal bone and parietal bone. A Fogarty catheter was inserted outside of the dura mater through the frontal hole, and its tip was guided out through the parietal hole using an arc-shaped needle. The SH group served as a control. In both groups, normal saline was injected into the balloon at 40 μL/minute until breathing stopped. Mechanical ventilation was instituted immediately and provided for another 6 hours after the determination of brain death.
RESULTS: Typical blood pressure patterns were observed in both groups during the brain death induction period, whereas the fluctuation seemed relatively mild in the DH group. Stable brain death with normotension for 6 hours was induced successfully in 18 rats (90%) in the DH group and in 9 rats (45%) in the SH group (P = .002). The mean arterial pressure at 3 hours and thereafter was significantly higher in the DH group compared to the SH group (P < .05).
CONCLUSIONS: Our results demonstrate that the DH method is a simple and effective technique to make the brain death model more stable and standardized, possibly due to precise control of the direction of the cannulation and the position of the balloon.
Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
The first example of applying salicylaldehyde derivatives, as well as coumarin with the formyl group at the C8 position in its structure, as carbonyl partners in a three-component Passerini reaction, is presented. As a result of research on the conditions of the Passerini reaction, the important role of the hydroxyl group in the salicylaldehyde used in the course of the multicomponent reaction was revealed. When an aldehyde with an unprotected hydroxyl group is used, only two-component α-hydroxy amide products are obtained. In contrast, the use of acylated aldehyde results in three-component α-acyloxy amide products with high efficiency. The developed protocol gives access to structurally diversified peptidomimetics with good yield. The compounds were also evaluated as antimicrobial agents against selected strains of nosocomial pathogenic bacteria. The structure-activity relationship revealed that inhibitory activity is strongly related to the presence of the trifluoromethyl group (CF3) or the methyl group at the C4 position in an unsaturated lactone ring of the coumarin scaffold. MIC and MBC studies were carried out on eight selected pathogenic bacteria strains (Gram-positive pathogenic Staphylococcus aureus strain (ATCC 23235), as well as on Gram-negative E. coli (K12 (ATCC 25404), R2 (ATCC 39544), R3 (ATCC 11775), and R4 (ATCC 39543)), Acinetobacter baumannii (ATCC 17978), Pseudomonas aeruginosa (ATCC 15442), and Enterobacter cloacae (ATCC 49141) have shown that the tested compounds show a strong bactericidal effect at low concentrations. Among all agents investigated, five exhibit higher antimicrobial activity than those observed for commonly used antibiotics. It should be noted that all the compounds tested showed very high activity against S. aureus, which is the main source of nosocomial infections that cause numerous fatalities. Additionally, the cytotoxicity of sixteen derivatives was measured with the use of the MTT test on BALB/c3T3 mouse fibroblast cell lines. The cytotoxicity studies revealed that the tested substances exert a similar or lower effect on cell proliferation than that observed for commonly used antibiotics within the range of therapeutic doses. A parallel MTT assay using ciprofloxacin, bleomycin, and cloxacillin showed that these antibiotics are more cytotoxic when tested in mammalian cells, and cell viability is in the range of 85.0-89.9%. Furthermore, we have shown that the studied coumarin-based peptidomimetics, depending on their structural characteristics, are nonselective and act efficiently against various Gram-positive and Gram-negative pathogens, which is of great importance for hospitalised patients.
A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
This study aims to investigate the potential causal relationship between cerebrospinal fluid (CSF) metabolites and Guillain-Barré syndrome (GBS) using a bidirectional two-sample Mendelian randomization (MR) approach. Publicly available summary data from genome-wide association studies (GWAS) were utilized for comprehensive analysis. The CSF metabolite GWAS summary data were extracted from a GWAS conducted by Panyard et al encompassing 338 CSF metabolites in European participants (n = 291). GWAS summary statistics for GBS were obtained from the FinnGen consortium (n = 215,931) comprising European populations. The primary method for MR analysis was the inverse variance weighted method. Various sensitivity analyses were conducted to assess the heterogeneity and pleiotropy of the findings. In the forward MR analysis, we identified a causal relationship between 15 CSF metabolites, including ribitol levels (odds ratio = 3.833, 95% confidence interval: 1.949-7.540, P = 9.87E-05), and the risk of developing GBS. In the reverse MR analysis, we found a causal relationship between GBS and 21 CSF metabolites, including gamma-glutamylphenylalanine levels (odds ratio = 0.934, 95% confidence interval: 0.904-0.966, P = 7.10E-05). No evidence of heterogeneity or horizontal pleiotropy was found in the MR analysis. Our findings suggest that the identified CSF metabolites and metabolic pathways can serve as valuable biomarkers for clinical screening and prevention of GBS. They may also be considered as candidate molecules for future research into the underlying mechanisms and for selecting drug targets.
FIELD: medicine, immunology. SUBSTANCE: invention relates to antibodies with reduced total positive charge. Invention involves composition containing monoclonal antibody conjugated with biotin, at least one among many free amino-groups occurring in antibody to obtain the modified antibody with reduced total positive charge as compared with that in untreated antibody, enhanced antigen-binding specificity. Invention relates also to method for preparing this composition and method for localization of antigen in mammalian body. Advantage of invention involves the enhancement of antibodies specificity and the improvement of pharmacokinetic indices. EFFECT: improved and valuable properties of antibodies. 16 cl, 3 tbl, 19 dwg, 28 ex
In 3 double-blind placebo-controlled clinical trials, 1126 CKD patients on dialysis received study drug (656 Sensipar®, 470 placebo) for up to 6 months. The most frequently reported adverse events (incidence of at least 5% in the Sensipar® group and greater than placebo) are provided in Table 2. The most frequently reported events in the Sensipar® group were nausea, vomiting, and diarrhea.

The incidence of serious adverse events (29% vs. 31%) was similar in the Sensipar® and placebo groups, respectively.

12-Month Experience with Sensipar®:  Two hundred and sixty-six patients from 2 phase 3 studies continued to receive Sensipar® or placebo treatment in a 6-month double-blind extension study (12-month total treatment duration). The incidence and nature of adverse events in this study were similar in the two treatment groups, and comparable to those observed in the phase 3 studies.

Postmarketing Experience with Sensipar®: Rash, hypersensitivity reactions (including angioedema and urticaria), diarrhea and myalgia have been identified as adverse reactions during post-approval use of Sensipar®. Isolated, idiosyncratic cases of hypotension, worsening heart failure, and/ or arrhythmia have been reported in Sensipar®-treated patients with impaired cardiac function in postmarketing safety surveillance. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cerebral Palsy (CP) is the most common childhood disorder that occurs with a lesion in the developing infant brain, seen in 2-3/1000 live births. CP is a posture, movement and tone disorder that occurs due to prenatal or postnatal causes. It is not progressive, but since the anatomy of the lesion and the physical development of the individual are not completed, the course of the disorder may vary throughout life. Accompanied by motor dysfunctions, it varies according to clinical types. In addition to this, various visual, sensory and behavioral problems, speech disorders that cause learning difficulties and cognitive problems can also be observed. Ophthalmic disorders are the most common problem in CP and can also affect the developmental process of the patient. Since ophthalmic disorders and neurological deficits are associated in CP, the relationship between neurological disorder and ophthalmic disorders has been investigated in the literature. Studies show that 60-70% of children with CP also have CVI. CVI is defined as a lack of visual function resulting from damage or disruption of the retrogeniculate visual pathways (optic radiations, occipital cortex, visual associative areas) in the absence of any major ocular disease. This involvement of the retrogeniculate visual pathways is common in CP, given that the lesions most commonly underlying this condition also affect the visual areas of the brain. CVI is defined as bilateral loss of central visual function (visual acuity) caused by neurological damage to the visual cortex and⁄or visual pathway structures. It is most commonly caused by hypoxic ischemia causing periventricular leukomalacia (PVL) in the preterm infant. Disturbance of the oculomotor system is also typical in CP. Abnormalities in functions such as fixation, tracking and saccadic movements; Strabismus and abnormal ocular movements are also frequently described. With the participation of visual relational areas, visual perception and integration disorders, which are often seen as visual cognitive disorders, can occur when the child reaches school age. These impairments should be investigated even when visual functions such as visual acuity and visual field are normal or mildly impaired.Gross Motor Classification System (GMFCS) and Manual Skill Classification System (MACS) are used by clinicians to obtain a clear picture of how motor skills of individuals with CP, mobility levels in daily life and independence levels of hand functions are affected. However, although it is known that children with CP have visual effects, the methods in which visual functions are classified are insufficient. Therefore, Baranello et al. A tool has been developed to classify the visual function classification system. The aim of this study is to establish the Turkish validity and reliability of the Visual Function Classification System (VFCS) specific to individuals with Cerebral Palsy (CP).
Protocol for colorectal neoplasia patients who need surgery by modifying the current one. Until now, in the preoperative time, the anesthetist evaluated the need for some specific action such as pre-operative iron administration to avoid perioperative transfusions or the need to assess some of the patient's morbidities to try to optimize it. In the perioperative period in our hospital, the criteria of the Multimodal and Fast-Tcack Rehabilitation programs have been applied for a long time and there are some trajectories that allow standardization of patient management once they have been admitted.

It is demonstrated in other centers and in other surgical pathologies that, in addition to what we are already applying to our center, modify the preoperative preparation of our patients and try to improve their "functional capacity" results of lower morbidity and mortality and the subsequent recovery of patients can greatly improve . This is called prehabilitation. Pretreatment consists in a change in preoperative preparation at three levels. The concept of preoperative preparation changes and the patient is actively involved in it. Three levels of the patient are controlled: functional or physical level, nutritional level and emotional level, by means of pots and they are encouraged to make a series of changes in their habitual life (exercise, dietary advice, mindfullness techniques) that increase its functional capacity. This is related to a decrease in morbidity and mortality and in addition to a better and faster postoperative recovery.
Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency causes an accumulation of glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells". Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside. In clinical trials VPRIV reduced spleen and liver size, and improved anemia and thrombocytopenia.

In this lysosomal storage disorder (LSD), clinical features are reflective of the accumulation of Gaucher cells in the liver, spleen, bone marrow, and other organs. The accumulation of Gaucher cells in the liver and spleen leads to organomegaly. Presence of Gaucher cells in the bone marrow and spleen lead to clinically significant anemia and thrombocytopenia.
An anionic hydrophilic,  proteinase  sensitive novel compound,  antibodies  to the novel compound and methods for preparing the novel compound are disclosed. The novel compound has a molecular weight of less than 3,000 daltons and is obtained from a  mammal.  The novel compound  stimulates   sperm  motility  by   increasing curvilinear  velocity  and  lateral  head  amplitude  and decreasing linearity of swimming track and beat cross frequency.  Processes for detecting fertile mammalian eggs and sperm using the novel compound are disclosed.  Methods for  assaying  fertility of  a mammal;  for  identifying substances which are capable of binding to the novel compound and; for identifying substances which affect the ability of mammalian sperm to increase sperm motility in response to the novel compound, using the novel compound are also disclosed.  Diagnostic kits for carrying out the methods are disclosed.
Acute Renal Failure (ARF)is a severe inflammatory disease state often accompanied by Multi-Organ Failure (MOF) and Systemic Inflammatory Response Syndrome (SIRS). ARF is precipitated by many factors and is most often linked to the loss of kidney tubule cell function. Patients with ARF are treated in the intensive care units of hospitals and recovery of renal function is vitally important to their survival. Current therapy for ARF involves conventional kidney support with continuous renal replacement therapies (CRRT). Despite advances in treating patients with CRRT, ARF has an extremely high mortality rate (55-70%) and requires extensive hospital stays, predominantly in the ICU. The RAD is designed to both treat ARF with MOF and/or SIRs and facilitate the natural recovery of a patient's own kidney function. The RAD is intended for use for short periods of time in conventional extracorporeal therapeutic systems that are already available in the hospital. The RAD therapy operates outside the body, and is designed to mimic the structure and function of the natural kidney. In this manner it is intended to replace the missing metabolic, endocrine, and immunologic functions of the kidney and allow time for the patient's own kidneys to resume normal functions.
OBJECTIVE: The unique metastatic pattern of skip lateral lymph node metastasis (SLLNM) in PTC patients may lead to missed diagnosis of lateral cervical metastatic lymph nodes. Therefore, many different SLLNM prediction models were constructed. In this study, partially eligible models (Hu 2020, Wang 2020, and Zhao 2023 nomograms) were selected for external validation, and then new variables were incorporated for model reconstruction to extend clinical applicability.
METHODS: 576 PTC patients from our center were selected to evaluate the performance of the three nomograms using the receiver operating characteristic curve (ROC), calibration curves, and decision curve analyses (DCA). Three new variables were added to calibrate the model, including assessment of LN status on ultrasound (US-SLLNM), the distance from the tumor to the capsule (Capsular distance), and the number of central lymph node dissections (CLND number). Univariate and multivariate logistic regression analyses were used to screen independent predictors to reconstruct the model, and 1000 Bootstrap internal validations were performed.
RESULTS: SLLNM were present in 69/576 patients (12.0%). In external validation, the area under the ROC curves (AUCs) for Hu 2020, Wang 2020, and Zhao 2023 nomograms were 0.695 (95% CI:0.633-0.766), 0.792 (95% CI=0.73-0.845), and 0.769 (95% CI:0.713-0.824), respectively. The calibration curves for the three models were overall poorly fitted; DCA showed some net clinical benefit. Model differentiation and net clinical benefit improved by adding three new variables. Based on multivariate analysis, female, age, and maximum tumor diameter ≤ 10 mm, located at the upper pole, Capsular distance < 0mm, US-SLLNM, CLND number ≤ 5 were identified as independent predictors of SLLNM and were used to construct the new model. After 1000 Bootstrap internal validations, the mean AUC of the model was 0.870 (95% CI:0.839-0.901), the calibration curve was close to the ideal curve, and the net clinical benefit was significant.
CONCLUSION: Overall, these nomograms were well differentiated and provided some net clinical benefit, but with varying degrees of underestimation or overestimation of the actual risk and high false-negative rates. New dynamic nomogram was constructed based on the addition of new variables and larger samples, showing better performance.